Finally, considering that Sildenafil has been safely used during more than two decades (39) and that recent results in heart failure patients are certainly promising (93), we suggest that Sildenafil treatment would represent an appropriate opportunity for immediately access to a less expensive and more secure novel therapeutic alternative to treat severe cardiac pathologies characterized by exacerbated NHE1 activity. This evidence concerns the gene SLC9A1 and heart failure.